Compare Fubotv Inc (FUBO) vs Novartis AG (NVS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Fubotv Inc vs Novartis AG — how do they compare? Fubotv Inc trades at $9.21 (market cap $1.02B), while Novartis AG trades at $143.81 (market cap $268.57B). The key difference: Novartis AG is far larger — about 263.3× Fubotv Inc's market cap, and Novartis AG pays a 3.31% dividend while Fubotv Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Fubotv Inc for 35 Days and Novartis AG for 82 Days on average.
| FUBO | NVS | |
|---|---|---|
Market Cap | $1.02B | $268.57B |
Volume | 978,631 | 1,532,573 |
Sector | Media | Health |
52-Week High | $48.96 | $168.62 |
52-Week Low | $8.09 | $121.80 |
Typical Hold Time | 35 Days | 82 Days |
Enterprise Value | $1.19B | $309.89B |
Dividend Yield | — | 3.31% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
FUBO trades at $9.25, up 4.76% today, showing technical bearish signals with mixed earnings performance. The company reported Q2 2026 EPS of -$0.25, beating expectations, but missed in Q4 2025. Revenue growth has been strong, reaching $1.62B in 2024 with improving profit margins. Recent developments include new sports streaming agreements and Disney partnership integration driving subscriber growth.
FUBO presents a speculative opportunity with deep valuation discounts (P/E 2.43, P/S 0.19) but faces execution risks amid persistent cash burn. Analyst consensus is mixed with 47% buy ratings and $63.38 price target, representing significant upside potential if turnaround succeeds. Key risks include competitive pressure and path to sustained profitability.
Novartis (NVS) trades at $143.28, up 1.77% on the day, with a neutral technical signal and mixed earnings history. The company reported strong 2025 revenue of $56.67B and a net income margin of 22.5%, supported by a recent $7.8B licensing deal with China's Abogen. However, recent clinical trial setbacks and an ongoing law firm investigation introduce uncertainty.
The outlook is balanced; solid profitability and a consensus price target of $146.00 suggest modest upside, but risks from pipeline failures and heightened M&A scrutiny warrant caution. Investor sentiment is mixed, with analysts predominantly holding a neutral stance amid evolving business developments.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Fubotv Inc
FuboTV Inc is a sports-first, live TV streaming company, offering subscribers access to tens of thousands of live sporting events annually as well as news and entertainment content. Its platform, fuboTV, allows customers to access content through streaming devices and on SmartTVs, mobile phones, tablets, and computers. The company offer subscribers a live TV streaming service with the option to purchase incremental features available for purchase that include additional content or enhanced functionality best suited to their preferences. The operating segments of the group are Streaming and Online wagering, of which a majority of revenue is derived from the Streaming segment. It has a business presence in the U.S. and other international countries.
Read more on FUBO →About Novartis AG
Novartis develops and manufactures healthcare products through two segments: Innovative Medicines and Sandoz. It generates the vast majority of its revenue from Innovative Medicines segment consisting global business franchises in oncology, ophthalmology, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States representing close to one third of total revenue.
Read more on NVS →
